Hansoh Pharmaceutical Group Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Huijuan Zhong

Geschäftsführender

CN¥14.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	49.6%
Amtszeit als Geschäftsführer	8.5yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	8.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.7yrs

Jüngste Management Updates

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06

Recent updates

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Jun 24

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06

Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

May 23

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 01

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Mar 28

There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

Mar 04

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Feb 16

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Dec 08

Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Oct 12

Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

Sep 14

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Sep 09

Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jul 10

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Jun 11

Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jan 23

Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Dec 01

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Oct 19

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Aug 28

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Jun 09

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

May 19

Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?

Apr 22

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued

Feb 06

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 43% Above Its Share Price

Nov 07

Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Oct 11

A Look At The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jul 14

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Huijuan Zhong im Vergleich zu den Einnahmen von Hansoh Pharmaceutical Group verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	CN¥15m	CN¥7m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥3b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥11m	CN¥5m	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥3b
Dec 31 2021	CN¥16m	CN¥8m	CN¥3b

Vergütung im Vergleich zum Markt: HuijuanDie Gesamtvergütung ($USD2.04M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD891.40K).

Entschädigung vs. Einkommen: HuijuanDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Huijuan Zhong (63 yo)

8.5yrs

Amtszeit

CN¥14,807,000

Vergütung

Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Huijuan Zhong	Chairlady	8.5yrs	CN¥14.81m	keine Daten
Aifeng Lyu	Executive Director	8.3yrs	CN¥9.39m	0.023% CN¥ 23.2m
Yuan Sun	Executive Director	8.5yrs	CN¥16.63m	0.021% CN¥ 20.8m
Min Hu	VP & CFO	no data	keine Daten	keine Daten
Chih-Hung Lee	Chief of Science Officer	2.2yrs	keine Daten	keine Daten
Chuanhe Xu	Senior Vice President	15.3yrs	keine Daten	keine Daten
Weiyong Sun	Chief Commercial Officer	no data	keine Daten	keine Daten
Shengli Zhong	Joint Company Secretary & Senior VP	5.8yrs	keine Daten	keine Daten
Sze Wai Tam	Joint Company Secretary	less than a year	keine Daten	keine Daten

8.3yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrenes Management: 3692Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.3 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Huijuan Zhong	Chairlady	8.5yrs	CN¥14.81m	keine Daten
Aifeng Lyu	Executive Director	8.3yrs	CN¥9.39m	0.023% CN¥ 23.2m
Yuan Sun	Executive Director	8.5yrs	CN¥16.63m	0.021% CN¥ 20.8m
Guoqiang Lin	Independent Non-Executive Director	5.1yrs	CN¥360.00k	keine Daten
Sheung Wai Chan	Independent Non-Executive Director	5.1yrs	CN¥360.00k	keine Daten
Dongtao Yang	Independent Non-Executive Director	5.1yrs	CN¥360.00k	keine Daten

6.7yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: 3692Die Vorstandsmitglieder gelten als erfahren (6.6 Jahre durchschnittliche Amtszeit).

Hansoh Pharmaceutical Group Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Executive Director exercised options to buy HK$1.1m worth of stock.

Executive Director exercised options to buy HK$5.9m worth of stock.

Insufficient new directors

Recent updates

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Now 21% undervalued

Upcoming dividend of HK$0.14 per share

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Now 21% undervalued

Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Full year 2023 earnings: EPS exceeds analyst expectations

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Consensus EPS estimates increase by 16%

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Full year 2023 earnings: EPS exceeds analyst expectations

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 24% undervalued after recent price drop

There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Now 20% undervalued

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 12%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Upcoming dividend of HK$0.071 per share at 1.4% yield

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

Investor sentiment deteriorates as stock falls 19%

Now 25% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Executive Director exercised options to buy HK$1.1m worth of stock.

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.8% yield

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Executive Director exercised options to buy HK$5.9m worth of stock.

Full year 2022 earnings: EPS and revenues miss analyst expectations

Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Investor sentiment improved over the past week

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Insufficient new directors

Investor sentiment improved over the past week

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.05 per share

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022

First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment improved over the past week

Executive Director exercised options to buy HK$1.3m worth of stock.

Upcoming dividend of HK$0.09 per share

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing